Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 17-27

  Wilson, Robert ^a   Anzueto, Antonio ^b   Miravitlles, Marc ^e   Arvis, Pierre ^f   Alder, Jeff ^c   Haverstock, Daniel ^c   Trajanovic, Mila ^g   Sethi, Sanjay ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f Bayer HealthCare ^*  (France)

^g Bayer Inc   (Canada)

Author keywords

Acute exacerbations of chronic obstructive pulmonary disease; Amoxicillin clavulanic acid; Antibiotic; Clinical trial design; Exacerbation; Moxifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CORTICOSTEROID; MOXIFLOXACIN;

ADULT; ANAPHYLAXIS; ARTICLE; BACTERIAL INFECTION; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BACTERIUM IDENTIFICATION; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMEMBRANOUS COLITIS; RADIAL NERVE PALSY; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; SPIROMETRY; SPUTUM CULTURE; TACHYCARDIA; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLINES; TREATMENT OUTCOME;

EID: 84863458014     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00090311     Document Type: Article

References (52)

1. Miravitlles M, Ferrer M, Pont A, et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A 2 year follow-up study. Thorax 2004; 59: 387-395. (Pubitemid 38624744)
2. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006; 61: 250-258.
3. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213.
4. Wilkinson T, Wedzicha JA. Strategies for improving outcomes of COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2006; 1: 335-342.
5. Blanchard AR. Treatment of acute exacerbations of COPD. Clin Cornerstone 2003; 5: 28-36.
6. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006; 119: Suppl. 1, S38-S45.
7. Sethi S. Antibiotics in acute exacerbations of chronic bronchitis. Expert Rev Anti Infect Ther 2010; 8: 405-417.
8. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852. (Pubitemid 35178607)
9. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 15: 332-338.
10. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-685. (Pubitemid 36976277)
11. Dever LL, Shashikumar K, Johanson WG. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs 2002; 11: 911-925. (Pubitemid 34732710)
12. Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127-1137. (Pubitemid 46895371)
13. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. (Pubitemid 41829947)
14. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2010. Available from: www.goldcopd.org. Date last accessed: May 7, 2011.
15. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008; 15: Suppl. A, 1A-8A.
16. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
17. Spencer S, Jones PW, GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-593. (Pubitemid 36808129)
18. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 369-374.
19. Wilson R, Anzueto A, Miravitlles M, et al. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int J Chron Obstruct Pulmon Dis 2011; 6: 373-383.
20. Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964. (Pubitemid 38367286)
21. Calver AD, Walsh NS, Quinn PF, et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24: 570-574. (Pubitemid 27143549)
22. European Medicines Agency. ICH Topics E6 (R1) Guideline for Good Clinical Practice. Step 5. Note for Guidance on Good Clinical Practice CCPMP/ICH/135/95. London, EMEA, 2006. www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002874.pdf
23. Clinical Laboratory Standards Institute. CLSI Document MA07-A8, Wayne, CLSI, 2009.
24. Wilson R, Jones P, Schaberg T, et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337-342.
25. Aaron SD, Fergusson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008; 63: 122-128. (Pubitemid 351236474)
26. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-1352. (Pubitemid 30321589)
27. Petitpretz P, Choné C, Trémolières F, et al. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents 2007; 30: 52-59. (Pubitemid 46874906)
28. Nalepa P, Dobryniewska M, Busman T, et al. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr Med Res Opin 2003; 19: 411-420. (Pubitemid 36994444)
29. Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007; 55: 226-232. (Pubitemid 47244922)
30. Miravitlles M, Espinosa C, Fernández-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-46. (Pubitemid 29340258)
31. Albertson TE, Louie S, Chan AL. The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis. J Am Geriatr Soc 2010; 58: 570-579.
32. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2: 191-204. (Pubitemid 350110894)
33. Alvarez-Sala JL, Kardos P, Martínez-Beltrán J, et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006; 50: 1762-1767.
34. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231-2236.
35. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
36. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-2625. (Pubitemid 36741589)
37. Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150-157.
38. Roede BM, Bresser P, Bindels PJ, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008; 63: 968-973.
39. Niewoehner DE. Clinical practice. Outpatient management of severe COPD. N Engl J Med 2010; 362: 1407-1416.
40. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456. (Pubitemid 36173708)
41. Allegra L, Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005; 99: 742-747. (Pubitemid 40631301)
42. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009; 103: 601-606.
43. Stockley RA, O'Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645. (Pubitemid 30413357)
44. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2011; 52: Suppl. 4, S290-S295.
45. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. (Pubitemid 38807371)
46. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147: 633-638. (Pubitemid 351664484)
47. Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 43: Suppl. A, 107-113.
48. Dimopoulos G, Siempos II, Korbila JP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132: 447-455. (Pubitemid 47282375)
49. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
50. Doll H, Duprat-Lomon I, Ammerman E, et al. Validity of the St George's respiratory questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham health profile. Qual Life Res 2003; 12: 117-132. (Pubitemid 36255777)
51. Bax R. Development of a twice daily dosing regimen of amoxicillin/clavulanate. Int J Antimicrob Agents 2007; 30: Suppl. 2, S118-S121.
52. Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and development of amoxicillin/clavulanate. Int J Antimicrob Agents 2007; 30: Suppl. 2, S109-S112.